Identifing medical predictors of anti-hypertensive effect of eplerenone

Identifing medical predictors of anti-hypertensive effect of eplerenone - IMPRESSIVE Study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002479

Enrollment

Registered

2009-09-11

Start date

2009-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Interventions

Administer 50mg of eplerenone for one month and check blood pressure. For another month upscale 50mg to 100mg of eplerenone and re-check anti-hypertensive effect.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patient with high blood pressure (systolic BP>140mmHg and/or diastolic BP>90mHg)

Exclusion criteria

Exclusion criteria: 1. renal dysfunction (eGFR<50ml/min or male Cr>2.0mg/dl, female Cr>1.8mg/dl) 2. liver dysfunction 3. serum K>5.0mEq/l before intervention 4. diabetes

Design outcomes

Primary

Measure	Time frame
Correlation between aldosterone/renin ratio before administration of eplerenone and anti-hypetensive effect.	—

Secondary

Measure	Time frame
Correlation between other parameters, which include BMI, waist circumference, gender, urinary Na excretion, urinary aldosterone, urinary free cortisol, renal 11beta-hydroxysteroid dehydrogenase activity, serum K, creatinine, ANP, BNP, and urinary 8OHdG, and anti-hypetensive effect.	—

Countries

Japan

Contacts

Public ContactHirotaka Shibata

School of Medicine, Keio University Internal Medicine

hiro-405@cb3.so-net.ne.jp

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026